Scribd Logo
Upload

Welcome to Scribd!

  • 19 views

    Pfizer Dosage Chart

    Uploaded by

    Hwy
    This document provides dosage information for the Pfizer-BioNTech COVID-19 vaccine based on a recipient's age. It specifies that those ages 5-11 should receive the orange-capped formulation at a dose of 0.2 mL, while those 12 and older should receive the purple-capped version at 0.3 mL. An additional dose is authorized for moderately or severely immunocompromised individuals ages 12 and older. Booster doses are recommended for those 16 and older at least 6 months after completing their primary series.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd

    Pfizer Dosage Chart

    Uploaded by

    Hwy
    19 views1 page
    This document provides dosage information for the Pfizer-BioNTech COVID-19 vaccine based on a recipient's age. It specifies that those ages 5-11 should receive the orange-capped formulation at a dose of 0.2 mL, while those 12 and older should receive the purple-capped version at 0.3 mL. An additional dose is authorized for moderately or severely immunocompromised individuals ages 12 and older. Booster doses are recommended for those 16 and older at least 6 months after completing their primary series.

    Copyright

    © © All Rights Reserved

    Available Formats

    PDF, TXT or read online from Scribd

    Did you find this document useful?

    Is this content inappropriate?

    This document provides dosage information for the Pfizer-BioNTech COVID-19 vaccine based on a recipient's age. It specifies that those ages 5-11 should receive the orange-capped formulation at a dose of 0.2 mL, while those 12 and older should receive the purple-capped version at 0.3 mL. An additional dose is authorized for moderately or severely immunocompromised individuals ages 12 and older. Booster doses are recommended for those 16 and older at least 6 months after completing their primary series.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    19 views1 page

    Pfizer Dosage Chart

    Uploaded by

    Hwy
    This document provides dosage information for the Pfizer-BioNTech COVID-19 vaccine based on a recipient's age. It specifies that those ages 5-11 should receive the orange-capped formulation at a dose of 0.2 mL, while those 12 and older should receive the purple-capped version at 0.3 mL. An additional dose is authorized for moderately or severely immunocompromised individuals ages 12 and older. Booster doses are recommended for those 16 and older at least 6 months after completing their primary series.

    Copyright:

    © All Rights Reserved
    Download as PDF, TXT or read online from Scribd
    Download as pdf or txt
    You are on page 1of 1

    5 Years of Age and Older

    Pfizer-BioNTech COVID-19 Vaccine


    Vaccine Dosage Chart

    The table below summarizes dosage information based on age, dose and medical indications for Pfizer-BioNTech COVID-19 Vaccine
    formulations. Use this table in conjunction with the FDA Fact Sheet for Healthcare Professionals and CDC clinical materials.
    ƒ Use the correct formulation for the age of the recipient. ƒ All Pfizer-BioNTech vaccines are administered by intramuscular
    Formulations are NOT interchangeable. Check the vial label (IM) injection. The injection site depends on recipient's age:
    to ensure you are preparing and administering the correct ‚ 5 through 11 years of age: Deltoid muscle (preferred)
    formulation based on the age of the recipient.
    ‚ 12 years of age and older: Deltoid muscle
    ‚ 5 through 11 years of age: Orange cap and orange bordered label
    ‚ Vastus lateralis muscle in the anterolateral thigh may
    ‚ 12 years of age and older: Purple cap and purple bordered label be used.
    ƒ Vaccine must be mixed BEFORE administering. Use 0.9%
    preservative-free normal saline diluent supplied in the ancillary
    supplies kit. Diluent is not packaged with the vaccine.

    PRIMARY SERIES DOSES


    Primary Series (People 5 years of age and older)
    If administering Recipient’s age Use Mix vaccine using Administer

    5 through 11 years of age


    5 through 11 years of age 1.3 mL of diluent* 0.2 mL
    formulation (orange cap)
    Primary series: Dose 1 or 2
    (Separate by at least 21 days)
    12 years of age and older
    12 years of age and older 1. 8 mL of diluent* 0.3 mL
    formulation (purple cap)

    Additional Primary Dose for Moderately and Severely Immunocompromised Persons


    If administering Recipient’s age Use Mix Vaccine Using Administer
    Any dose in the series An additional dose for moderately and severely immunocompromised children
    5 through 11 years of age
    (include the primary in this age group has NOT been authorized by FDA or recommended by CDC.
    2-dose series and an
    additional dose given at 12 years of age and older
    least 28 days after the 12 years of age and older 1. 8 mL of diluent* 0.3 mL
    formulation (purple cap)
    primary series)

    BOOSTER DOSES
    Booster Doses
    If administering Recipient’s age Use Mix vaccine using Administer

    A booster dose in this age group has NOT been authorized by FDA or
    5 through 15 years of age
    recommended by CDC.
    Booster dose (at least 6
    calendar months after
    completing the primary
    series†)
    16 years of age and 12 years of age and older
    1.8 mL of diluent* 0.3 mL
    older‡ formulation (purple cap)

    *  0.9% normal saline (preservative-free)


    †  Including the additional primary series dose for moderately and severely immunocompromised persons. If Janssen (Johnson & Johnson) COVID-19 Vaccine was administered as the
    primary dose, the booster dose should be administered 2 months after receipt of Janssen vaccine.
    ‡  A booster dose of COVID-19 vaccine should be administered to all persons 18 years of age or older and may be administered to 16 and 17 year olds based on their individual benefits and
    risks. Additional information can be found at: www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html#considerations-covid19-vax-booster

    1
    12/15/2021 CS321570-U

    You might also like